Status:
RECRUITING
Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding
Lead Sponsor:
Xingshun Qi
Conditions:
GastroIntestinal Bleeding
Eligibility:
All Genders
18+ years
Brief Summary
Acute gastrointestinal bleeding is potentially lethal in liver cirrhosis. Accurate assessment of prognosis is critical in a timely fashion. A novel model, CAGIB score, has been developed based on our ...
Eligibility Criteria
Inclusion
- Patients with liver cirrhosis;
- Patients with acute gastrointestinal bleeding presenting with hematemesis, melena, and/or hematochezia;
- Adults (age≥18 years old).
Exclusion
- Components of Child-Pugh, MELD, and CAGIB scores are not available;
- In-hospital outcomes are not evaluable.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT04662918
Start Date
January 1 2022
End Date
December 1 2025
Last Update
October 7 2025
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
The Wright Center for Graduate Medical Education, 501 S. Washington Avenue
Scranton, Pennsylvania, United States, 18503
2
São Paulo State University (UNESP), Botucatu Medical School
São Paulo, São Paulo, Brazil
3
Beijing Youan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
4
The Seventh Medical Center of Chinese PLA General Hospital
Beijing, Beijing Municipality, China